AI Article Synopsis

  • Respiratory syncytial virus (RSV) is a major cause of severe respiratory illnesses in young children and poses significant risks to the elderly and immunocompromised adults.
  • There's a promising development of RSV vaccines and treatments expected in Europe in the next 2-10 years, highlighting the need for a better understanding of the disease's impact on children.
  • A recent assessment in Belgium revealed limited data on RSV, with a recommendation to enhance surveillance and reporting systems to accurately evaluate the disease burden and improve management strategies.

Article Abstract

Unlabelled: Infections with respiratory syncytial virus (RSV) can cause severe disease. In young children, RSV is the most common cause of lower respiratory tract illness and life-threatening infections most commonly occur in the first years of life. In adults, elderly and immunocompromised people are most vulnerable. Recently there has been an acceleration in the development of candidate RSV vaccines, monoclonal antibodies and therapeutics which are expected to become available in Europe within the next 2-10 years. Understanding the true burden of childhood RSV disease will become very important to support public health authorities and policy makers in the assessment of new therapeutic opportunities against RSV disease. A systematic literature search was performed to map local data on the burden of RSV disease and to evaluate available RSV surveillance systems. A group of 9 paediatric infectious diseases specialists participated in an expert panel. The purpose of this meeting was to evaluate and map the burden associated with RSV infection in children, including patient pathways and the epidemiological patterns of virus circulation in Belgium. Sources of information on the burden of RSV disease in Belgium are very limited. For the outpatient setting, it is estimated that 5-10% of young patients seen in primary care are referred to the hospital. Around 3500 children between 0 and 12 months of age are hospitalized for RSV-bronchiolitis every year and represent the majority of all hospitalizations. The current Belgian RSV surveillance system was evaluated and found to be insufficient. Knowledge gaps are highlighted and future perspectives and priorities offered.

Conclusion: The Belgian population-based RSV surveillance should be improved, and a hospital-led reporting system should be put in place to enable the evaluation of the true burden of RSV disease in Belgium and to improve disease management in the future.

What Is Known: • RSV bronchiolitis is a very important cause of infant hospitalization. • The burden of disease in the community is poorly studied and underestimated.

What Is New: • This expert opinion summarizes knowledge gaps and offers insights that allow improvement of local surveillance systems in order to establish a future-proof RSV surveillance system.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660201PMC
http://dx.doi.org/10.1007/s00431-022-04698-zDOI Listing

Publication Analysis

Top Keywords

rsv disease
24
rsv surveillance
16
rsv
15
burden rsv
12
disease
9
disease young
8
young children
8
true burden
8
surveillance systems
8
disease belgium
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!